Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07075471 · ClinicalTrials.gov registry record
Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
A clinical trial of Tenosynovial Giant Cell Tumor, sponsored by Deciphera Pharmaceuticals.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT07075471: Recruiting study of Tenosynovial Giant Cell Tumor, sponsored by Deciphera Pharmaceuticals.
NCT07075471 is a study of Tenosynovial Giant Cell Tumor that is actively recruiting participants, run by Deciphera Pharmaceuticals. The registered enrollment target is 100 participants, roughly in line with the 105-participant average among 8 other Tenosynovial Giant Cell Tumor trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07075471, a study of Tenosynovial Giant Cell Tumor, is actively recruiting participants, sponsored by Deciphera Pharmaceuticals.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.
Conditions Studied
Study Locations (1)
North Carolina
- Synexus Clinical Research, US INC - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-09-03 |
| Est. Completion | 2027-09 |
What NCT07075471 shows while recruiting
NCT07075471 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 105-participant average among 8 other Tenosynovial Giant Cell Tumor trials with a reported enrollment target.
The record links to 1 condition, with Tenosynovial Giant Cell Tumor appearing as the primary indexed condition, and to 0 interventions.
NCT07075471 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT07075471 about?
NCT07075471 is a clinical study titled "Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib". The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the pa...
What is the current status of trial NCT07075471?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-09-03. Estimated completion is 2027-09.
What conditions does trial NCT07075471 study?
This clinical trial studies the following conditions: Tenosynovial Giant Cell Tumor.
Who is sponsoring clinical trial NCT07075471?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07075471 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tenosynovial Giant Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07075471's enrollment target sits among peer trials
100 5th of 8 higher than 4 of 8 other Tenosynovial Giant Cell Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tenosynovial Giant Cell Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
RECRUITING · Phase 1
-
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
RECRUITING
-
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
ACTIVE NOT RECRUITING · Phase 3
-
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
ACTIVE NOT RECRUITING · Phase 1
-
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI